Brief: Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

Stoke Therapeutics

11/01/2026 19:03

Jan 11 (Reuters) - Stoke Therapeutics Inc STOK.O:

STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME

STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027

STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS

Source text: ID:nBw1dlkjsa

Further company coverage: STOK.O

 ((Reuters.briefs@thomsonreuters.com;))